Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care,...
Study published in Nature Communications finds cancer-targeted molecular imaging agent with needle-based confocal laser endomicroscopy system...
Following its 2021 restructuring, Company experiences stable U.S sales growth, including improved gross margin and anticipated reductions in...
Completion of a Major Regulatory Milestone for Molecular Imaging and Precision Medicine as Part of Ongoing Collaboration Mauna Kea...
The collaboration will explore and establish the value of molecular image-guided procedures for the identification and diagnosis of pulmonary...
Study will advance the validation of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy that may reduce the...
READ THE COMPLETE PRESS RELEASE
Global 2021 sales grew +18% year-over-year to €7.7M Mauna Kea Technologies announced fourth quarter and full year 2021 sales. Total...
Corporate resources focused on highest value clinical applications Significant reduction in operating expenses implemented Cash runway now extended...
Company to focus resources on robotic assisted interventional pulmonology and molecular imaging Nicolas Bouvier, member of the Executive Committee,...
Proven diagnostic accuracy of Cellvizio allows for successful downstaging of non-mucinous lesions and prevention of unnecessary surgeries, resulting...
Mauna Kea Technologie announced third quarter and first nine months of 2021 sales results for the periods ended September 30, 2021. First...
